- Home
- OLMA vs PVLA Comparison
OLMA vs PVLA Comparison
Compare OLMA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- PVLA
- Stock Information
- Founded
- OLMA 2006
- PVLA 2015
- Country
- OLMA United States
- PVLA United States
- Employees
- OLMA N/A
- PVLA N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- OLMA Health Care
- PVLA Health Care
- Exchange
- OLMA Nasdaq
- PVLA Nasdaq
- Market Cap
- OLMA 299.7M
- PVLA 285.2M
- IPO Year
- OLMA 2020
- PVLA N/A
- Fundamental
- Price
- OLMA $5.76
- PVLA $53.42
- Analyst Decision
- OLMA Strong Buy
- PVLA Strong Buy
- Analyst Count
- OLMA 5
- PVLA 11
- Target Price
- OLMA $24.00
- PVLA $56.64
- AVG Volume (30 Days)
- OLMA 532.6K
- PVLA 156.2K
- Earning Date
- OLMA 08-11-2025
- PVLA 08-14-2025
- Dividend Yield
- OLMA N/A
- PVLA N/A
- EPS Growth
- OLMA N/A
- PVLA N/A
- EPS
- OLMA N/A
- PVLA N/A
- Revenue
- OLMA N/A
- PVLA N/A
- Revenue This Year
- OLMA N/A
- PVLA N/A
- Revenue Next Year
- OLMA N/A
- PVLA N/A
- P/E Ratio
- OLMA N/A
- PVLA N/A
- Revenue Growth
- OLMA N/A
- PVLA N/A
- 52 Week Low
- OLMA $2.86
- PVLA $11.17
- 52 Week High
- OLMA $13.93
- PVLA $53.93
- Technical
- Relative Strength Index (RSI)
- OLMA 63.92
- PVLA 85.86
- Support Level
- OLMA $5.34
- PVLA $46.08
- Resistance Level
- OLMA $5.78
- PVLA $50.22
- Average True Range (ATR)
- OLMA 0.34
- PVLA 3.11
- MACD
- OLMA 0.05
- PVLA 0.70
- Stochastic Oscillator
- OLMA 85.90
- PVLA 97.00
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.